Comparative Pharmacology
Head-to-head clinical analysis: BETHKIS versus GENOSYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETHKIS versus GENOSYL.
BETHKIS vs GENOSYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin, an aminoglycoside antibiotic, binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis, leading to bacterial cell death.
Genosyl (sodium phenylbutyrate) is a prodrug that is metabolized to phenylacetate, which conjugates with glutamine via acetylation to form phenylacetylglutamine. This alternative pathway facilitates waste nitrogen excretion in patients with urea cycle disorders.
4 IU/kg (1 mg/kg) intramuscularly or subcutaneously once weekly for 4 weeks, then a maintenance dose of 2 IU/kg (0.5 mg/kg) once weekly.
5 mg orally once daily for 14 days, then 2.5 mg orally once daily thereafter.
None Documented
None Documented
Terminal elimination half-life 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 3.5 hours; clinically relevant for dosing every 6-8 hours in renal impairment.
Primarily renal excretion of unchanged drug via glomerular filtration; ~90% of absorbed dose excreted in urine within 24 hours; biliary/fecal elimination <5%.
Renal: 85% unchanged; biliary/fecal: 15% as metabolites.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic